aTyr Pharma, Inc. (ATYR) Stock Score, Valuation & Financial Research
aTyr Pharma, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 18/100.
Quick answer for ATYR
aTyr Pharma, Inc. currently has a Wall Street Score of 18/100. The stored market price is $0.38. Its financial score is 12/100. Its valuation score is 0/100. The latest WSS change is +0.2 points. These figures are a research snapshot, not a buy or sell recommendation.
What aTyr Pharma, Inc. does
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in prec
ATYR financial snapshot
- Wall Street Score:
- 18/100
- Current price:
- $0.38
- Market capitalization:
- $37.7M
- Revenue:
- $190K
- Net income:
- $-60.8M
- Free cash flow:
- $-62.1M
- Cash:
- $16.2M
- Total debt:
- $11.3M
- EPS:
- -0.62
- Financial score:
- 12/100
- Valuation score:
- 0/100
- Revenue score:
- 0/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-62.1M, showing cash burn in the current stored period.
- The balance sheet shows $16.2M of cash versus $11.3M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +0.2 points: ATYR increased 0.2 points because Asset improved by 2.2 points.
- The current research record carries a corporate distress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 12/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research ATYR
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.